Edwards Lifesciences (EW) EBT Margin (2009 - 2026)

Edwards Lifesciences' EBT Margin history runs 18 years deep, the most recent figure standing at 27.84% for Q1 2026.

• On a quarterly basis, EBT Margin fell 287.0% year-over-year to 27.84% in Q1 2026; TTM through Mar 2026 was 20.59%, a 858.0% decrease from a year earlier, with the FY2025 full-year figure at 20.98%, down 748.0% from the prior year.
• EBT Margin advanced to 27.84% in Q1 2026 per EW's latest filing, from 5.76% in the prior quarter.
• Across five years, EBT Margin topped out at 49.17% in Q4 2022 and bottomed at 5.76% in Q4 2025.
• The 5-year median for EBT Margin is 29.0% (2023), against an average of 28.67%.
• Across the five-year window, EBT Margin soared 2087 bps in 2022 and tumbled 2239 bps in 2025, its largest moves.
• Year by year, EBT Margin stood at 49.17% in 2022, then sank by 41 bps to 29.0% in 2023, then dropped by 3 bps to 28.15% in 2024, then slumped by 80 bps to 5.76% in 2025, then soared by 383 bps to 27.84% in 2026.
• Per Business Quant, the three latest EW EBT Margin figures stand at 27.84% (Q1 2026), 5.76% (Q4 2025), and 22.43% (Q3 2025).